Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$14.90 USD

14.90
4,622,217

-2.97 (-16.62%)

Updated May 8, 2024 04:00 PM ET

After-Market: $14.89 -0.01 (-0.07%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden

Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.

5 Top-Performing Liquid Stocks for Attractive Returns in 2021

Here are five top-ranked liquid stocks -- Intuit (INTU), National Vision (EYE), Lindsay Corporation (LNN), Magnolia Oil & Gas (MGY) and Buckle (BKE) -- which investors can tap for attractive returns.

Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.

Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.

West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

Bowen Center Expands Access to Care via NextGen's (NXGN) Platform

NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.

Amedisys' (AMED) Contessa Buyout to Boost Home Health Business

Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.

3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio

Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.

Trina Mukherjee headshot

3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic

Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio

Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.

Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe

Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.

Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre

Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.

Charles River (CRL) Advances in Gene Therapy With Vigene Buyout

The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.

Here's Why You Should Buy National Vision (EYE) Stock Now

Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.

Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data

Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.

Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research

Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.

SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes

SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout

Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.

Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake

Boston Scientific (BSX) currently holds an equity stake of roughly 27%.

Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues

Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.

OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal

OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.